MUMBAI, India and PRINCETON, N.J., March 21, 2018 /PRNewswire/ — Sun Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn) for the treatment of adults with…Original Article
FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
